Objectives: To study the effects of short term intermediate dose glucocorticoid therapy in patients with active rheumatoid arthritis (RA) on circulating endothelial progenitor cells (EPC), which are known to influence cardiovascular risk, and to elucidate mechanisms potentially responsible for the reduction of EPCs in patients with active RA.
Methods: EPC were quantified in 29 patients with active RA by flow cytometry, colony forming unit (CFU) and circulating angiogenic cell (CAC) assays before and after 7 days of intermediate dose glucocorticoid therapy. CFU from RA patients and from healthy referents (HR) were cultured in vitro in the absence or presence of dexamethasone (Dex) and/or TNF.
Results: After one week of glucocorticoid therapy, EPC increased from 0.026+/-0.003 % to 0.053+/- 0.010 % (p<0.01), and from 12+/-4 to 27+/-7 CFU/well (p<0.02); CAC also increased from 7+/-2 to 29+/-8 cells/high power field (p<0.05). In parallel, disease activity decreased significantly after glucocorticoid treatment. TNF serum levels also decreased from 36+/-10 to 14+/-6 pg/ml (p<0.0001). Addition of Dex to the RA CFU led to a significant increase of mean CFU counts, whereas addition of TNF induced a decrease of CFU.
Conclusions: Our data indicate that TNF may be at least partly responsible for the reduction of EPC seen in RA patients. Intermediate doses of glucocorticoids for a short period of time, aside of reducing disease activity, significantly increase circulating EPC.
- endothelial progenitor cells
- rheumatoid arthritis
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.